ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1454

Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis

Julie Di Paolo1, David Alonzo2, Christian Franci3, Terry Gentzler1, Li Li4, Bernard Murray5 and Jim Zheng5, 1Biology, Gilead Sciences, Foster City, CA, 2FPD, Gilead Sciences, Foster City, CA, 3Biology, Gilead Sciences, Foster, CA, 4Gilead Sciences, South San Francisco, CA, 5DMPK, Gilead Sciences, Foster City, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Animal models, Janus kinase (JAK), kinase and rheumatoid arthritis, SYK

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Rheumatoid Arthritis – Animal Models - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   Spleen Tyrosine Kinase (SYK) mediates signaling in hematopoietic cells important for the initiation and progression of rheumatoid arthritis (RA). GS-9876 is an oral, selective SYK inhibitor being developed in RA. Janus kinase (JAK) inhibitors, have demonstrated clinical efficacy in RA and exert their biological activity principally by blockade of proinflammatory cytokine signaling. Here we demonstrate that 1) the single agent activity of GS-9876 is efficacious in a late stage rat model of collagen-induced arthritis (CIA); 2) the combination of GS-9876 with a JAK inhibitor increases efficacy in this model; and 3) the effects of targeting SYK or JAK as single agents can be functionally differentiated.

Methods:   The in vivo efficacy of GS-9876 and a JAK inhibitor were tested alone or in combination in a therapeutic rat CIA model. Dosing was initiated at the peak of disease (day 17-20) and continued into the chronic phase until day 34; making the test more indicative of late treatment effects in the highly destructive macrophage-mediated phase, rather than in the acute, early neutrophil mediated phase of t this model. Efficacy evaluations were based on animal body weights, daily ankle caliper measurements, ankle diameter (expressed as area under the curve), terminal hind paw weights, and histopathology of ankles and knees. Anti-type II collagen antibody levels in terminal serum were analyzed, and PK was collected to evaluate the relationship to efficacy. Joint tissue RNA and protein were analyzed for transcriptional and protein modulation.

Results:  GS-9876 demonstrated dose-responsive efficacy in the rat CIA model. GS-9876 or a JAK inhibitor alone showed efficacy on clinical and histopathology parameters. Administration of the SYK or JAK inhibitor in combination showed significantly alleviated increases in terminal paw weights, ankle swelling, and ankle histopathology scores than either agent alone. Body weight loss was also significantly reduced in the combination therapy group, and weight was increased compared to the monotherapy arms. Knee ED-1 immunopositive osteoclast counts were significantly reduced in the animals treated with GS-9876, but not a JAK inhibitor, highlighting functionally distinct effects of SYK and JAK inhibition. PK analysis of GS-9876 showed serum exposure levels similar to those achieved in human studies.

Conclusion:   GS-9876 is a novel SYK inhibitor which displays in vivo therapeutic efficacy in a chronic rat CIA model. Combining GS-9876 with JAK inhibition significantly improved clinical and histopathology scores, and reduced body weight loss in this model, at exposures similar to those achieved in healthy human volunteers. These data suggest that simultaneously targeting SYK and JAK can provide an efficacious therapy for inflammatory diseases.


Disclosure: J. Di Paolo, Gilead Sciences, Inc, 1,Gilead Sciences, Inc, 3; D. Alonzo, Gilead Sciences, 1; C. Franci, Gilead Sciences, 1; T. Gentzler, Gilead Sciences, 1; L. Li, Gilead, 3; B. Murray, Gilead Sciences, 1; J. Zheng, Gilead Sciences, 1.

To cite this abstract in AMA style:

Di Paolo J, Alonzo D, Franci C, Gentzler T, Li L, Murray B, Zheng J. Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/combination-of-the-syk-inhibitor-gs-9876-with-a-jak-inhibitor-increases-efficacy-in-a-chronic-rat-model-of-collagen-induced-arthritis/. Accessed February 27, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/combination-of-the-syk-inhibitor-gs-9876-with-a-jak-inhibitor-increases-efficacy-in-a-chronic-rat-model-of-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.